The United States has been imposing tariffs on China in a crazy manner, with President Trump claiming this would bring manufacturing back to America. But can American industries truly break free from "Made in China"?
According to an April 23 report by The New York Times, the U.S. once dominated the global market for personal protective equipment (PPE), now, with the flood of Chinese medical supplies, over 90% of the medical gear used by American healthcare workers is made in China. As one U.S. medical equipment executive bluntly put it: even with a 100 percent tariff, the Chinese masks is still going to be cheaper than the American-made masks.
The report highlights that few American industries have been hit as hard by cheap Chinese imports as manufacturers of masks, exam gloves, and other disposable medical gear. The sector’s decline had led to catastrophic consequences during the COVID-19 pandemic. When China temporarily halted exports, American healthcare workers found themselves defenseless as the deadly airborne virus rapidly filled up emergency rooms and morgues.
Now, with Trump announcing a new round of tariffs this month and China retaliating with an 84% tariff on U.S. imports, the handful of American PPE manufacturers left felt mostly unease.
Lloyd Armbrust, CEO of Armbrust American, a Texas-based N95 mask producer, admitted, "I’m pretty freaked out. On one hand, this is the kind of medicine we need if we really are going to be independent of China. On the other hand, this is not responsible industrial policy."
The U.S. once led the world in PPE, inventing the N95 mask and disposable gloves. Yet today, over 90% of the medical equipment worn by American healthcare staff is produced in China.
During the first year of the pandemic, more than 100 new American medical supply companies sprang up. Five years later, nearly all have vanished. As the pandemic receded, demand for PPE fell. For many Americans, masks became a symbol of government overreach and loss of freedom. Chinese products then returned to the market.
Despite bipartisan vows to end reliance on foreign medical supplies and support the dozens of domestic manufacturers that emerged during the pandemic, federal agencies have reverted to buying inexpensive Chinese imports. Industry experts warn that, with the ongoing measles outbreak, avian flu threats, and the trade war with China, renewed dependence on imported medical products is especially concerning.
According to the American Medical Manufacturers Association, of the 107 companies founded during the pandemic, only five still produce masks and gloves.
Eric Axel, the association’s executive director, says that maintaining high tariffs on Chinese PPE would give U.S. manufacturers an edge: "I think it will change behavior, because people will have to adjust to the reality that you can’t buy below-market price rate stuff from China anymore."
Other industry leaders fear that an escalating U.S.-China trade war could disrupt supply chains and trigger fresh PPE shortages. Tariff policies also breed economic uncertainty, stifling new investment. Scott McGurl, a healthcare industry expert at consulting firm Grant Thornton, notes, "It’s difficult to make business decisions when policies change every four years, and now every couple of days."
Mike Bowen, now-retired but still a shareholder of Prestige Ameritech, one of the few pre-pandemic American mask makers, said the collapse of the U.S. PPE industry in recent years was entirely predictable. He had repeatedly warned Congress about the risks of relying on foreign-made PPE, but no lessons were learned.
Earlier, when California bought millions of N95 masks for residents affected by the Los Angeles wildfires, they chose Chinese products.
Some American medical equipment manufacturers believe that what’s needed now is legislation and policy mandates to push government agencies and hospitals to buy American-made masks and gloves.
Yet, as Armbrust American’s Lloyd Armbrust points out: "Even with a 100% tariff, the Chinese mask that sells for a penny is still going to be cheaper than an American-made mask selling for eight cents."
Deep Throat
** The blog article is the sole responsibility of the author and does not represent the position of our company. **
Trump wasted not one second after US forces grabbed Venezuelan President Nicolás Maduro. He made it clear that he was eyeing the country's oil riches. But here's the catch: America's biggest oil companies aren't biting. Industry analysts confirm what the companies won't say publicly—even if these firms wanted back in, Venezuela's crumbling infrastructure and chaos on the ground mean Trump's fantasy of quick oil profits is far from easy to come true.
Trump promises Big Oil will pour billions into Venezuela. The oil giants say they never got the memo. AP Photo
Minutes after the military operation wrapped, Trump stood at a press conference making promises. Major American oil companies would pour into Venezuela, he declared, investing billions to fix the country's shattered oil infrastructure "and start making money for the country". Meanwhile, he reiterated that the US embargo on all Venezuelan oil remains in full effect.
Those sanctions have crushed Venezuelan exports into paralysis. Documents from Venezuela's state oil company and sources close to the situation confirm storage tanks and floating facilities filled up fast over recent weeks. Multiple oil fields now face forced production cuts.
White House Courts Reluctant Executives
Reuters revealed the Trump administration plans meetings this week with executives from major US oil companies. The agenda: pushing these firms to restore and grow oil production in Venezuela following the military action. The White House sees this as a critical step toward getting American oil giants back into the country to tap the world's largest proven oil reserves.
But Trump's eagerness hasn't translated into corporate enthusiasm. Several major US oil companies are taking a wait-and-see approach, watching Venezuela closely. ExxonMobil, ConocoPhillips, and Chevron all denied any prior communication with the White House about Venezuela. This directly contradicts Trump's claim over the weekend that he had already met with "all" US oil firms both before and after Maduro's capture.
Venezuela sits on roughly 17% of the world's proven oil reserves—first place globally. Yet US sanctions and other pressures have gutted its production capacity. Current output runs around 1 million barrels daily, barely 0.8% of global crude production.
World's largest oil reserves, strangled by US sanctions. Trump's quick-profit scheme hits a hard reality. AP Photo
Only One Company Stays Put
Chevron remains the sole major US oil company still operating Venezuelan fields. The firm has worked in Venezuela for over a century, producing heavy crude that feeds refineries along the Gulf Coast and beyond. A company spokesperson said on the 3rd that the current priority centers on "ensuring employee safety, well-being, and asset integrity," adding they "will continue to operate in accordance with laws and regulations."
ExxonMobil and ConocoPhillips previously invested in Venezuela. In the 1970s, the Venezuelan government nationalized the oil industry, reopened to foreign investment by century's end, then demanded in 2007 that Western companies developing oil fields form joint ventures with Venezuelan firms under Venezuelan control. ExxonMobil and ConocoPhillips pulled out. Neither company has responded to Trump's latest remarks about US capital entering Venezuela.
One oil industry executive told Reuters that companies fear discussing potential Venezuelan business at White House-organized meetings due to antitrust concerns.
Benefits Flow to First Mover
Francisco Monaldi, director of the Latin America Energy Program at Rice University's Baker Institute for Public Policy, expects Chevron would likely benefit first if Venezuela opens oil projects to the US. Other oil companies, he notes, will watch Venezuela's political situation closely and observe the operating environment and contract compliance before making moves.
Mark Christian, business director at an Oklahoma energy consulting firm, lays out the baseline: US companies will only return to Venezuela if they're certain of investment returns and receive at least minimal security guarantees. Lifting sanctions on Venezuela stands as a prerequisite for US companies re-entering that market.
Reality Check on Oil Profits
Even with sanctions lifted, the Trump administration won't find making money from invasion-acquired oil that easy.
Industry insiders admit large-scale restoration of Venezuelan oil production demands years of time and billions in investment, while confronting major obstacles: dilapidated infrastructure, uncertain political prospects, legal risks, and long-term US policy uncertainty.
Peter McNally, global head of industry analysis at Third Bridge, said, "There are still many questions that need to be answered about the state of the Venezuelan oil industry, but it is clear that it will take tens of billions of dollars to turn that industry around." He then added that it could take at least a decade of Western oil majors committing to the country.
Ed Hirs, an energy expert at the University of Houston, pointed to a pattern: US military invasions of other countries in recent years haven't delivered substantial returns to American companies. The history of Iraq and Libya may repeat itself in Venezuela.
